Quick Summary — ALKS scores higher on quality with 8.7/10 vs ANIP's 8.4/10. ALKS trades at $41.32 while ANIP trades at $74.65. Both analyzed daily using SEC EDGAR data across 13 institutional models.
ALKS scores higher with a 8.7/10 quality rating vs ANIP's 8.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $41.32, ALKS trades +67.8% above its Bayesian DCF fair value of $13.30, while ANIP at $74.65 trades +37.7% above its estimate of $46.47. ALKS shows a wider gap between price and intrinsic value.
ALKS earns a Quality of Company score of 8.7/10 compared to ANIP's 8.4/10. The scores are closely matched, indicating similar fundamental quality profiles. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
ALKS carries a SAFE value trap risk (12/100) while ANIP shows SAFE risk (24/100). Both companies show manageable value trap risk, suggesting their current valuations are not artificially depressed by fundamental deterioration.
Both ALKS and ANIP operate in Drug Manufacturers - Specialty & Generic, which has 79 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare ALKS vs ANIP differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.